With Siegfried as preferred partner, our customers can expect significant benefits. Bringing together our long-standing pharma and chemical heritage, we offer as an integrated supplier benefit to our customers with more synergy, expertise and value.
Explore more about how our broad range of custom development services, drug substance & drug product manufacturing capabilities, together with our existing product portfolio may help you achieve greater value.
As an internationally recognized outsourcing partner, Siegfried provides products and tailor made services that integrate seamlessly into a customer’s value chain. The company offers pharmaceutical industry partners a comprehensive range of services – from development of drug substances to product development, registration and manufacturing to packaging and logistics. Once a fully integrated pharmaceutical company, Siegfried is one of the few suppliers today that can provide both the drug substance and the drug product development and production capabilities. This combination of know-how and experience is unique for a supplier of development and production services.
Siegfried has expanded its technology base and geographic presence around the world in the past years. In addition to technological competence and a global presence, full compliance for all products and work processes to ensure safety is a high priority. The company adheres to the most rigorous requirements and quality guidelines in development, production and marketing. Siegfried’s reputation in this area is confirmed by a seamless performance record for audits – carried out by regulatory authorities and clients.
Its production facilities are located in Switzerland, the USA, Malta, China, Germany and France. In 2017, the company achieved net sales of CHF 750.5 million and currently employs approximately 2300 people. Siegfried Holding AG is publicly listed on the Swiss Stock Exchange in Zurich (SIX: SFZN).
To be a world-class service partner in the development and manufacture of drug substances and drug products that improve life.
Siegfried at the end of 2015 successfully finalized the “Transform” strategy. During this phase characterized by impressive sales and earnings growth, the company became the worldwide leading supplier and service provider of chemically produced active pharmaceutical ingredients for the pharmaceutical industry and entered the business segment of sterile finished products. The follow-up strategy “Evolve” will continue the success story and the growth dynamics at a high level. The core of the “Evolve” strategy aims to reinforce Siegfried’s position as the leading integrated supplier to the pharmaceutical industry. The related key areas are targeted expansion of existing business, improved product offer along the value chain, and diversification into adjoining business segments.
Three strategic pillars for continued growth
The measures chosen to implement the “Evolve” strategy are essentially based upon three pillars:
1. An improved product range for customers is to be achieved, especially, by means of worldwide expansion into solid finished drug dosage forms (tablets, capsules). Today, Siegfried’s production in this area is based in Hal Far (Malta) and since the acquisition of the drug product manufacturing facility from Arena Pharmaceuticals GmbH in the spring 2018 as well in Zofingen (Switzerland).,The corresponding pharmaceutical development is located in Zofingen. By means of an acquisition, either in North America or in Europe, Siegfried aims to gain access to additional competitive capacity and formulation technologies. Siegfried plans to expand production capacity hand in hand with further strengthening development competencies.
2. Growth initiatives within the value chain of the existing business will make a significant contribution toward targeted growth and the expansion of critical size of sales. Siegfried focuses on the recently commenced plant expansion in Hameln, which serves the sterile filling of chemically produced APIs. The capacity includes production lines for ampoules and vials. The extensions permit technically challenging aseptic filling of sensitive bio-pharmaceutical APIs, which currently are administered to patients usually in liquid form via syringes. In view of above-average growth forecasts in this segment and the high entry barriers for competitors, Siegfried will participate in a market segment expected to remain attractive in the long run. A first step in this direction is represented by the strategic partnership with Symphogen, a Danish bio-pharmaceutical company, in terms of which Siegfried Hameln produced the first biologics last year.
3. The third pillar of “Evolve” concerns the diversification into adjoining business segments through targeted investment in technological capabilities or the acquisition of companies, giving Siegfried access to new technologies and market segments. As physical properties of APIs, for example, play a significant role in the receptivity of drugs by the human organism, we plan, in the coming years, to invest in micronization (miniaturization of drug substance particles, e.g. powder), expansion of existing competencies in spray drying (drying process used in production of powders) or lyophilization (freeze drying) of demanding APIs. Moreover, we plan to establish additional facilities for the production of highly effective substances.
Pharmapark Siegfried is one of the most attractive pharma parks with a 140-year-old tradition. It is located in the center of the life science cluster in the northwest of Switzerland in close proximity to the international airports of Zurich and Basel (easy to reach within about one hour). More than 10 years of industry-related inspections by the FDA resulted in «no action indicated». On site, an effective fire brigade enjoys the support of all companies operating in the pharmaceutical park and ensures the highest level of safety. Besides numerous buildings with laboratories, there is sufficient space for new construction (max. 15,000m2). Companies located at Pharmapark Siegfried enjoy tailor-made conditions to suit their needs and have access to all services required by a company active in the drug industry and producing under cGMP conditions.
Companies operating from Pharmapark Siegfried:
Siegfried employs about 600 people at the site Zofingen and is leading CMO partner for the global pharmaceutical sector. With nine production sites in six countries on three continents, Siegfried offers a global network.
Bilfinger Industrial Services AG
Approximately 50 people work for Bilfinger in Zofingen. The company undertakes the main part of engineering, maintenance and security at the site.
EBM Industriecontracting GmbH
EBM is responsible for the supply of power and gaz and for the waste disposal at the Pharmapark.
Celgene Chemicals Sarl
The US pharma company owns about 5% of reactor capacity in Zofingen and relates to Siegfried regarding Compliance, IT, and physical steps.
Arena Pharmaceuticals GmbH
The US start-up company Arena owns three floors of building 121 (Pharma production site) and relates to Siegfried regarding HR and IT.